

## Intrexon Corp

### COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 09-Jul-2013

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Subsidiary Companies..... 7

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 11

[Return to Table of Contents](#)

# Intrexon Corp

## COMPANY OVERVIEW

<b>Company Name</b>	Intrexon Corp
<b>Parent Company Name</b>	Intrexon Corp
<b>Website</b>	http://www.dna.com
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	7
<b>Number of Inactive Drugs</b>	5
<b>Number of Patents as Owner</b>	20
<b>Number of Patents as Third Party</b>	1
<b>Number of Deals</b>	19
<b>Key Indications</b>	Cancer,Autoimmune disease,Infectious disease,Melanoma,Alzheimers disease,Diabetes mellitus,Respiratory disease,Solid tumor,Stage III melanoma,Stage IV melanoma
<b>Key Target-based Actions</b>	IL-12 agonist,Alpha 1 antitrypsin stimulator,DDC gene stimulator,Ecdysone receptor modulator,ATP2A2 gene stimulator,Sarco endoplasmic calcium ATPase 2 modulator,Adiponectin receptor agonist,B-lymphocyte cell adhesion molecule stimulator,Beta defensin stimulator,Beta-galactosidase modulator,Bradykinin B2 receptor antagonist,C-type lectin domain protein 12A stimulator,CFTR stimulator,Casein modulator,Cyclooxygenase stimulator,Elongation factor 2 inhibitor,ErbB2 tyrosine kinase receptor inhibitor,Erythropoietin ligand,GSK3 gene modulator,Glucagon-like peptide 1 agonist,Glucagon-like peptide 2 agonist,Glycogen synthase kinase-3 modulator,IL agonist,IL-10 agonist,IL-2 receptor alpha subunit stimulator,Interferon agonist,Interferon alpha ligand,Interferon beta ligand,Interferon gamma ligand modulator,Kallikrein inhibitor,Leptin agonist,MEK protein kinase modulator,Mesothelin stimulator,Myelin basic protein stimulator,Neural cell adhesion molecule stimulator,Plasma protease C1 inhibitor inhibitor,Plasminogen activator inhibitor 1 modulator,Protein phosphatase 1 inhibitor,RANTES ligand,Sarco endoplasmic calcium ATPase stimulator,Signal transducer CD24 stimulator,TNF alpha ligand,TNF gene modulator,Trophoblast glycoprotein stimulator,mTOR inhibitor,mTOR
<b>Key Technologies</b>	Biological therapeutic,Monoclonal antibody human,Parenteral formulation unspecified,Protein recombinant,Nanoparticle formulation,Gene transfer system viral,Peptide,Cell therapy,Antibody conjugated,Antibody polyclonal,Intratumoral formulation,Oral formulation,Subcutaneous formulation

## COMPANY PROFILE

### SUMMARY

Intrexon Corp (formerly Genomatix) is a privately-held life science company which researches and develops DNA control systems for the delivery, targeting, activation, regulation and location of biotherapeutics. The company changed its corporate name to Intrexon in August 2005.

### COMPANY LOCATION

The company has its headquarters in Blacksburg, VA, with additional R&D operations in Valley Forge, PA.

In October 2011, Intrexon launched a cell engineering unit in San Diego, CA.

In February 2011, Intrexon launched its Agricultural Biotechnology Division in Research Triangle Park, North Carolina.

In April 2010, Intrexon relocated its Protein Production Division from San Francisco, CA to Foster City, CA.

### ACQUISITIONS AND SPIN-OFFS

[Return to Table of Contents](#)



In October 2012, Intrexon entered into a definitive agreement to acquire an approximately 48% interest in Aqua Bounty Technologies by purchasing 48,631,444 shares for \$6 million in cash. Following the close of the transaction, Intrexon would be required to commence a tender offer for any and all of the other outstanding shares of Aqua Bounty. In January 2013, Intrexon chose not to extend the tender offer to acquire outstanding shares in Aqua Bounty.

In October 2011, Intrexon acquired Immunologix, a company focused on the production of fully human monoclonal antibodies.

In October 2011, Intrexon announced the acquisition of GT Life Sciences, and the purchase of assets comprising the LEAP cell-processing platform from Cyntellect. Terms of the transactions were not disclosed.

In April 2011, the company acquired Neugenesis.

In February 2011, Intrexon acquired Agarigen a company which developed a mushroom-based expression platform for rapid, high-yield production of recombinant proteins.

In September 2009, Intrexon acquired certain assets and operations from Clinical Data's subsidiary Avalon Pharmaceutical, including a bioassay facility in Germantown, MD, for \$1.5 million in cash.

In December 2006, RheoGene and Intrexon agreed to merge. The combined company, Intrexon Corp, would be based in Blacksburg, VA, and the UPMC would have an ownership stake in the new company.

## FINANCIAL

In May 2013, the company raised \$150 million from a series F preferred investment round.

In May 2011, Intrexon raised \$100 million from a series E preferred financing round.

In May 2008, Intrexon raised \$25 million from a series C-2 financing. In June 2009, the company raised an additional \$10 million from the series C-2 financing round.

In May 2007, Intrexon raised \$25 million from a series C financing round.

## SUBSIDIARY COMPANIES

Names
RheoGene Inc
Neugenesis Corp
Immunologix
Agarigen Inc

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Drugs by Indication Table


Indication	Active	Inactive	Total
Neoplasm	5	0	5

[Return to Table of Contents](#)

Infectious disease	1	4	5
Respiratory disease	1	3	4
Neurological disease	1	1	2
Dermatological disease	2	0	2
Gastrointestinal disease	1	0	1
Endocrine disease	1	0	1
Degeneration	1	0	1
Metabolic disorder	1	0	1
Immune disorder	1	0	1

### Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Phase 1 Clinical	1
Discovery	5
No Development Reported	5

[Return to Table of Contents](#)



## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	11	0	0	0	11
Drug - Funding	2	0	0	0	2
Drug - Early Research/Development	2	0	0	0	2
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Commercialization License	1	0	0	0	1
Drug - Development Services	1	0	0	0	1
Technology - Delivery/Formulation	0	0	2	0	2

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 1	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	7	0	7
Endocrine disease	1	0	1
Gastrointestinal disease	1	0	1
Genitourinary disease	2	0	2
Hematological disease	2	0	2

[Return to Table of Contents](#)



Degeneration	1	0	1
Immune disorder	6	0	6
Musculoskeletal disease	2	0	2
Neoplasm	14	0	14
Ocular disease	1	0	1
Genetic disorder	3	0	3
Metabolic disorder	4	0	4
Neurological disease	4	0	4
Respiratory disease	4	0	4
Infectious disease	5	0	5
Injury	1	0	1
Toxicity and intoxication	1	0	1
Unidentified indication	3	0	3
Inflammatory disease	4	0	4
Dermatological disease	4	0	4
Surgical procedure	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### Ad-RTS-IL-12

<b>Drug Name</b>	Ad-RTS-IL-12
<b>Key Synonyms</b>	
<b>Originator Company</b>	ZIOPHARM Oncology Inc
<b>Active Companies</b>	ZIOPHARM Oncology Inc, Intrexon Corp
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Stage IV melanoma, Stage III melanoma, Metastatic breast cancer
<b>Target-based Actions</b>	IL-12 agonist
<b>Other Actions</b>	Immunostimulant, Adenovirus based gene therapy, Anticancer
<b>Technologies</b>	Intratumoral formulation, Oral formulation, Virus recombinant, Biological therapeutic
<b>Last Change Date</b>	17-Jun-2013

### DC-RTS-IL-12

<b>Drug Name</b>	DC-RTS-IL-12
<b>Key Synonyms</b>	
<b>Originator Company</b>	Intrexon Corp
<b>Active Companies</b>	ZIOPHARM Oncology Inc, Intrexon Corp
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Solid tumor
<b>Target-based Actions</b>	IL-12 agonist
<b>Other Actions</b>	Immunostimulant, Anticancer, Genetically engineered autologous cell therapy
<b>Technologies</b>	Intratumoral formulation, Cell therapy, Oral formulation, Biological therapeutic
<b>Last Change Date</b>	10-May-2012

[Return to Table of Contents](#)



### rHuA1AT (sc Enhanze, A1AT deficiency), Intrexon

<b>Drug Name</b>	rHuA1AT (sc Enhanze, A1AT deficiency), Intrexon
<b>Key Synonyms</b>	
<b>Originator Company</b>	Intrexon Corp
<b>Active Companies</b>	Intrexon Corp
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Respiratory disease, Diabetes mellitus
<b>Target-based Actions</b>	Alpha 1 antitrypsin stimulator
<b>Other Actions</b>	Hypoglycemic agent
<b>Technologies</b>	Subcutaneous formulation, Biological therapeutic, Protein recombinant
<b>Last Change Date</b>	28-Mar-2012

### antibody drug conjugates (cancer), Intrexon

<b>Drug Name</b>	antibody drug conjugates (cancer), Intrexon
<b>Key Synonyms</b>	
<b>Originator Company</b>	Intrexon Corp
<b>Active Companies</b>	Intrexon Corp
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Antibody conjugated, Biological therapeutic
<b>Last Change Date</b>	28-Mar-2012

[Return to Table of Contents](#)



### fully human monoclonal antibodies (cancer/infection/autoimmune disease), Intrexon

<b>Drug Name</b>	fully human monoclonal antibodies (cancer/infection/autoimmune disease), Intrexon
<b>Key Synonyms</b>	
<b>Originator Company</b>	Immunologix
<b>Active Companies</b>	Intrexon Corp
<b>Inactive Companies</b>	Immunologix
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer, Infectious disease, Autoimmune disease
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antimicrobial, Immunomodulator, Anticancer monoclonal antibody
<b>Technologies</b>	Monoclonal antibody human, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	15-Jun-2012

### fully human mAbs (Alzheimers disease), Intrexon

<b>Drug Name</b>	fully human mAbs (Alzheimers disease), Intrexon
<b>Key Synonyms</b>	
<b>Originator Company</b>	Immunologix
<b>Active Companies</b>	Intrexon Corp
<b>Inactive Companies</b>	Immunologix
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Alzheimers disease
<b>Target-based Actions</b>	
<b>Other Actions</b>	Neuroprotectant
<b>Technologies</b>	Monoclonal antibody human, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	12-Jun-2012

[Return to Table of Contents](#)



## interferon-alpha plasmid transgene therapy (melanoma), ZIOPHARM/Intrexon

<b>Drug Name</b>	interferon-alpha plasmid transgene therapy (melanoma), ZIOPHARM/Intrexon
<b>Key Synonyms</b>	
<b>Originator Company</b>	ZIOPHARM Oncology Inc
<b>Active Companies</b>	Intrexon Corp, ZIOPHARM Oncology Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Melanoma
<b>Target-based Actions</b>	IFNA gene modulator
<b>Other Actions</b>	Immunostimulant, Plasmid based gene therapy, Anticancer
<b>Technologies</b>	DNA technology, Intramuscular formulation, Biological therapeutic
<b>Last Change Date</b>	19-Mar-2013

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

